Peptide-based research has expanded significantly since the early 2000s, driven by advances in peptide synthesis, better understanding of receptor biology, and growing interest in targeted approaches to metabolic, musculoskeletal, neurological, and aging-related biology. This overview maps the current landscape. This overview specifically addresses the peptide therapy research landscape, and related research is indexed on PubMed.
Why Peptides as Research Compounds?
Peptides offer several characteristics that make them attractive as research tools: high specificity for their receptor targets (reducing off-target effects in research models), relative ease of synthesis and modification, endogenous nature (many research peptides are analogs of naturally occurring molecules), and rapid degradation that can make them easier to study in controlled time windows.
Their main challenge as potential therapeutics is bioavailability: most peptides are rapidly degraded by proteases in the gut and bloodstream, have poor membrane permeability, and are rapidly renally cleared. Much pharmaceutical peptide research focuses on overcoming these limitations — through PEGylation, fatty acid conjugation, cyclization, or D-amino acid substitution.
Major Research Categories
Metabolic peptides: GLP-1 receptor agonists represent the most commercially successful peptide drug class of the past decade. They include fully approved drugs (semaglutide, tirzepatide, liraglutide) and investigational compounds (cagrilintide, retatrutide). This category has the strongest clinical evidence base of any research peptide area. Visit the GLP-1 Research Hub.
Tissue repair peptides: BPC-157, TB-500, GHK-Cu, and KPV are studied for healing and regeneration in animal models. This category has substantial animal model literature but very limited human clinical trial data.
Growth hormone secretagogues: CJC-1295, Ipamorelin, Sermorelin, MK-677, and GHRP-2/6 are studied for GH/IGF-1 axis modulation. Sermorelin has a regulatory history (FDA-approved for pediatric GHD). Others remain RUO compounds.
Cognitive and neuroprotective peptides: Selank, Semax, Dihexa, Epithalon, and Cerebrolysin are studied in neurological contexts. This category has a mix of Soviet/Russian clinical data and Western preclinical research.
Mitochondria-targeted peptides: SS-31, MOTS-c, and Humanin are studied in aging and energy metabolism contexts. SS-31 has reached Phase II human trials. This is among the most scientifically rigorous categories in the peptide research space.
Where the Evidence Is Strongest
Human clinical trial data exists for: GLP-1 receptor agonists (extensive RCT data), SS-31/elamipretide (Phase I/II), bremelanotide/PT-141 (FDA-approved), cerebrolysin (multiple controlled trials), and sermorelin (legacy FDA data). These represent the compounds with the most robust evidence base in the broader peptide research landscape.
Browse the full compound database with evidence-level labels for 88+ research compounds. Explore specific categories at the Peptide Research Hub or Nootropic Research Hub.
Peptide Drugs Are Now a Major, Fast-Growing Pharmaceutical Category
The scale of this field is easy to underestimate. As of 2025, the FDA recognized more than 130 approved peptide drug products as reference-listed drugs — a substantial and rapidly expanding category built on the same synthesis and structural principles discussed throughout this site. Market-size estimates for global peptide therapeutics vary considerably by analyst methodology (largely due to differing decisions about which insulin products and older peptide drugs to count), ranging from roughly $50 billion to well over $150 billion depending on the source and forecast year — but every major industry analysis agrees peptide therapeutics are among the fastest-growing drug classes in the pharmaceutical industry, driven substantially by the GLP-1 receptor agonist category’s commercial success.
Recent approvals illustrate the pace of this pipeline: orforglipron, an oral (non-injectable) GLP-1 receptor agonist from Eli Lilly, received FDA approval in April 2026 — notable because it’s a small-molecule-like oral peptide agonist rather than an injectable, addressing the bioavailability challenge described above through a fundamentally different formulation approach. Johnson & Johnson’s icotrokinra, an oral peptide IL-23 receptor antagonist for plaque psoriasis, received FDA approval in March 2026, demonstrating that peptide drug development is expanding well beyond metabolic disease into immunology and other therapeutic areas.
A Practical Evidence-Tiering Framework for This Landscape
Given how uneven evidence quality is across the categories on this page, it’s useful to sort any specific peptide claim into one of four rough tiers before weighing it: (1) FDA-approved with completed Phase 3 human trials (semaglutide, tirzepatide, bremelanotide/PT-141 as Vyleesi) — the strongest tier; (2) peptides with meaningful published human data short of full approval (GHK-Cu’s topical dermatology trials fall here); (3) peptides with an extensive preclinical (animal/in vitro) literature but no completed human trials (BPC-157, TB-500, most GH secretagogues); and (4) peptides with a thin, non-independently-replicated, or single-source evidence base. Applying this tiering consistently — rather than treating “extensively researched” as a single undifferentiated category — is the single most useful habit for reading peptide research critically, and it’s the framework implicitly used throughout the articles on this site.
Frequently Asked Questions
Why do peptide market-size estimates vary so much between sources?
Largely methodology — different analysts include or exclude certain insulin products, older peptide drugs, and adjacent biologics differently, which meaningfully shifts the total figure even when underlying growth trends agree.
Does an oral peptide drug like orforglipron mean the bioavailability problem is “solved”?
Not universally — orforglipron represents a specific formulation and molecular design breakthrough for that particular compound class, not a general solution applicable to all peptides; oral bioavailability remains a significant, compound-specific engineering challenge across the field.
Is a large or growing market size itself evidence that a specific compound works?
No — market size reflects commercial and investment activity across the category as a whole, not the evidence quality of any individual unapproved research compound discussed within it.
Educational research reference only. Not medical advice. Always evaluate evidence levels critically before drawing conclusions from peptide research.
